A bi-endpoint expectation-maximisation algorithm for re-estimating sample size for the time-to-event endpoint under the blind condition

被引:0
作者
Xie, Longshen [1 ]
Lu, Hui [1 ]
机构
[1] Shanghai Jiao Tong Univ, SJTU Yale Joint Ctr Biostat & Data Sci, Sch Life Sci & Biotechnol, Dept Bioinformat & Biostat, Shanghai 200240, Peoples R China
关键词
adaptive design; blinded sample size re-estimation; EM algorithm; interim analysis; time-to-event endpoint; ERROR RATE; SURVIVAL; CHEMOTHERAPY; REESTIMATION; INFLATION; CANCER;
D O I
10.1093/jrsssc/qlae019
中图分类号
O21 [概率论与数理统计]; C8 [统计学];
学科分类号
020208 ; 070103 ; 0714 ;
摘要
The expectation-maximisation (EM) algorithm can be used to adjust the sample size for the time-to-event endpoint without unblinding. Nevertheless, censoring or unreliable initial estimates may render inconsistent estimates by the EM algorithm. To address these limitations, we propose a bi-endpoint EM algorithm that incorporates the time-to-event endpoint and another endpoint, which can encompass various endpoint types and is not limited to efficacy indicators, during the EM iterations. Additionally, we suggest 2 approaches for choosing initial estimates. The application conditions are as follows: (i) at least one endpoint's initial estimate is reliable and (ii) the influence of this endpoint on the posterior distribution of the latent variable exceeds that of another endpoint.
引用
收藏
页码:935 / 954
页数:20
相关论文
共 34 条
[1]  
[Anonymous], 2007, Adaptive design methods in clinical trials
[2]   EVALUATION OF EXPERIMENTS WITH ADAPTIVE INTERIM ANALYSES [J].
BAUER, P ;
KOHNE, K .
BIOMETRICS, 1994, 50 (04) :1029-1041
[3]   Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non-Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses [J].
Blumenthal, Gideon M. ;
Karuri, Stella W. ;
Zhang, Hui ;
Zhang, Lijun ;
Khozin, Sean ;
Kazandjian, Dickran ;
Tang, Shenghui ;
Sridhara, Rajeshwari ;
Keegan, Patricia ;
Pazdur, Richard .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (09) :1008-+
[4]   Adaptive designs for confirmatory clinical trials [J].
Bretz, Frank ;
Koenig, Franz ;
Brannath, Werner ;
Glimm, Ekkehard ;
Posch, Martin .
STATISTICS IN MEDICINE, 2009, 28 (08) :1181-1217
[5]   MAXIMUM LIKELIHOOD FROM INCOMPLETE DATA VIA EM ALGORITHM [J].
DEMPSTER, AP ;
LAIRD, NM ;
RUBIN, DB .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-METHODOLOGICAL, 1977, 39 (01) :1-38
[6]  
European Medicines Agency, 2007, Reflection Paper on Methodological Issues in Confirmatory Clinical Trials with Flexible Design and Analysis Plan
[7]  
FDA, 2019, GUID IND AD DES CLIN
[8]  
Food and Drug Administration US Department of Health and Human Services, 2018, This publication describes the pivotal clinical trial leading to the FDA approval of fezolinetant
[9]   EM Algorithms for Weighted-Data Clustering with Application to Audio-Visual Scene Analysis [J].
Gebru, Israel Dejene ;
Alameda-Pineda, Xavier ;
Forbes, Florence ;
Horaud, Radu .
IEEE TRANSACTIONS ON PATTERN ANALYSIS AND MACHINE INTELLIGENCE, 2016, 38 (12) :2402-2415
[10]   PLANNING AND REVISING THE SAMPLE-SIZE FOR A TRIAL [J].
GOULD, AL .
STATISTICS IN MEDICINE, 1995, 14 (9-10) :1039-1051